Cellworks Wins Dell Technologies The Challengers 2022 Innovative Business of the Year Award. Read the press release - ow.ly/J0jV50KChyO
#Cellworks #StopAtNothing #innovation #DellTechnologies
CellworksLife
@CellworksLife
Cellworks is a world leader in Precision Medicine. We help physicians & payors navigate to efficacious cost effective treatments in a transparent, timely manner
CellworksLife’s Tweets
myCare-203A Clinical Study finds Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-guideline Genomic Factors
Read Press Release - cellworks.life/news-events/pr
#Cellworks #NSCLC #WCLC2022
Cellworks presents results of the myCare-203A trial at the IASLC World Conference on Lung Cancer. Read announcements and more - cellworks.life/WCLC
#WCLC2022 #NSCLC #Cellworks
1
Cellworks presents results of the myCare-203A trial at the IASLC World Conference on Lung Cancer. Read announcements and more - cellworks.life/WCLC
#WCLC2022 #NSCLC #Cellworks
1
2
Researchers find that using a GLI inhibitor, rather than a SMO inhibitor, make #medulloblastoma tumors smaller and weaker. Read the study - sciencedaily.com/releases/2022/
#BrainCancer
1
Cellworks Singula™ is a strong predictor of AML treatment outcomes. Read the study - ash.confex.com/ash/2021/webpr
#Cellworks #AML #Leukemia
2
2
#Pancreaticcancer is one of the deadliest forms of cancer. Read about the preclinical study that highlights a three-step treatment strategy to combat it.
medicalxpress.com/news/2022-07-p
#Oncology
1
Lung cancer: When radiotherapy fails - new findings to combat this deadly disease.
medicalxpress.com/news/2022-07-l
#LungCancer #Radiotherapy
1
Study shows it is possible to reverse a key process that allows pancreatic cancer cells to grow and spread around the body. Read article - sciencedaily.com/releases/2022/
#PancreaticCancer
2
2
Researchers discover new leukemia-killing compounds
medicalxpress.com/news/2022-06-l
#Leukemia #AML #Chemotherapy
1
Modern Myeloma Therapy + Sustained Minimal Residual Disease–Negative = (Functional) Cure!
ascopubs.org/doi/full/10.12
#MultipleMyeloma #Oncology
1
3
Hepatocellular carcinoma evades RB1-induced senescence by activating the FOXM1–FOXO1 axis
nature.com/articles/s4138
#HCC #HepatocellularCarcinoma #Oncology
1
Results of the myCare-004 study were presented at the ASCO Annual Meeting 2022.
Read the abstract - meetings.asco.org/abstracts-pres
#Cellworks #EsophagealAdenocarcinoma #ESAD #ASCO22
1
Results of the myCare-024-04 study were presented at the ASCO Annual Meeting 2022.
Read the abstract - meetings.asco.org/abstracts-pres
#Cellworks #GBM #ASCO22 #GlioblastomaMultiforme #BrainTumor
1
Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers - nature.com/articles/s4141
#BreastCancer #EndometrialCancer #OvarianCancer
1
New study finds biomarkers that could be drug targets against a deadly form of brain cancer
sciencedaily.com/releases/2022/
#Glioblastoma #GBM #BrainTumor
3
Predictions of OS and PFS for specific therapeutic interventions in newly diagnosed GBM using Cellworks Singula™ : myCare-024-04
Read the article - ascopubs.org/doi/abs/10.120
#Cellworks #GlioblastomaMultiforme #PersonalizedMedicine #ASCO22
June 17th is World Kidney Cancer Day. Fight cancer with Cellworks!
#Cellworks #KidneyCancer #RenalCarcinoma
1
Cellworks Singula™ therapy response index (TRI) predicts clinical outcomes for esophageal adenocarcinoma: myCare-004
Read the article - ascopubs.org/doi/abs/10.120
#Cellworks #ASCO22 #EsophagealAdenocarcinoma #PersonalizedMedicine
2
2
June is National Cancer Survivors Month - celebrate the warriors among us as we fight cancer together.
Fight Cancer with #Cellworks!
#PersonalizedMedicine #CancerSurvivor
June is National Cancer Survivors Month - celebrate the warriors among us as we fight cancer together.
Fight Cancer with #Cellworks!
#PersonalizedMedicine #CancerSurvivor
1
2
Proud to witness the launch of our TARGT Indiegene #IndiakaGenePanel as one of the "75 Products for the 75th Year of Independence" at Biotech Startup Expo 2022 organized by the and and inaugurated by our Hon'ble PM
4
6
Cellworks CMO Dr. Michael Castro speaks about Personalized Therapy Biosimulation at #ASCO22. Results of myCare-004 and myCare-024 studies were selected for poster presentations. Read abstracts and press release - cellworks.life/ASCO
#Cellworks #PersonalizedMedicine
2
3
4baseCare's TARGT Absolute is a CGP assay of ~20,000 genes that provide the necessary information by sequencing analysis of solid cancer-causing DNA/RNA variants and Immunotherapy markers for personalized cancer treatment.
LINK: bit.ly/39d8HEI
#MedTwitter
4
4
Results of the myCare-004 and myCare-024 clinical studies were featured in poster presentations at the ASCO Annual Meeting 2022.
Read press releases and more - cellworks.life/ASCO
#Cellworks #ASCO22 #PersonalizedMedicine
1
myCare-004 clinical study finds Cellworks Personalized Therapy Biosimulation provides superior OS, DFS and TRG predictions for gastroesophageal adenocarcinoma patients
Read press release - ow.ly/ThBv50Jqpib
#Cellworks #ASCO22 #EsophagealCancer
myCare-024-04 clinical study finds Cellworks Personalized Therapy Biosimulation provides superior OS and PFS predictions for GBM patients beyond standard clinical factors
Read press release - ow.ly/6Gge50JqoyR
#Cellworks #ASCO22
1
Results from myCare-024-04 study to be presented in poster session at the ASCO Annual Meeting 2022.
Read announcements and more - ow.ly/OEbK50JpW6z
#Cellworks #ASCO22 #GlioblastomaMultiforme
1
2
3
Results from myCare-004 study to be presented in poster session at ASCO Annual Meeting 2022.
Read announcements and more - cellworks.life/ASCO
#Cellworks #ASCO22 #EsophagealCancer
2
2
Cellworks to present two posters at the ASCO Annual Meeting 2022. Our studies find Cellworks TRI predicts survival beyond standard clinical factors.
Learn more - cellworks.life/ASCO
#Cellworks #ASCO22 #EsophagealCancer #GBM
Meet us at the ASCO 2022 Annual Meeting at booth #4071.
Go beyond population-based treatment to personalized therapy predictions with Cellworks.
Visit cellworks.life/ASCO to know more!
#ASCO22 #Cellworks
Meet us at the ASCO 2022 Annual Meeting at booth #4071.
Go beyond population-based treatment to personalized therapy predictions with Cellworks.
Visit cellworks.life/ASCO to know more!
#ASCO22 #Cellworks
1
Read about clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
nature.com/articles/s4140
#AML #Leukemia
1
1
TXN inhibitor impedes radioresistance of #ColorectalCancer cells with decreased ALDH1L2 expression via TXN/NF-κB signaling pathway. #Oncology
2
Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase. #BreastCancer #LungCancer
Regulatory T cells induce a suppressive immune milieu and promote lymph node metastasis in intrahepatic #cholangiocarcinoma. #Oncology
1
1
1
1

